MabVax Therapeutics Holdings, Inc. Announces Closing of Public Offering

Oct 05, 2015, 16:31 ET from MabVax Therapeutics Holdings, Inc.

SAN DIEGO, Oct. 5, 2015 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) ("MabVax"), a clinical-stage immuno-oncology drug development company, today announced that it has closed its previously announced public offering of 2,500,000 shares of its common stock and warrants to purchase up to 1,250,000 shares of its common stock.  For every two shares of common stock sold, MabVax issued one warrant to purchase one share of common stock. The shares and warrants were separately issued. The warrants are immediately exercisable, expire September 30, 2018 and have an exercise price of $1.32 per share. The warrants will not be listed on any securities exchange or other trading market.  The public offering price of the common stock was $1.10 per share. Gross proceeds to MabVax are approximately $2.75 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by MabVax.

MabVax intends to use the net proceeds from this offering to fully fund its HuMab 5B1 human antibody program through Phase I clinical development and for working capital and general corporate purposes.

Laidlaw & Company (UK) Ltd. acted as the sole book-running manager for the offering. 

MabVax has granted the underwriters a 30-day option to purchase up to an additional 375,000 shares of common stock and/or up to an additional 187,500 warrants at the same price to cover over-allotments, if any.

A registration statement relating to these securities was previously filed on Form S-1 (333-204803) with the Securities and Exchange Commission (the "SEC"), and was declared effective by the SEC on September 30, 2015. A final prospectus relating to the offering may be obtained on the SEC's website located at www.sec.gov, and electronic copies of the final prospectus may also be obtained from Laidlaw & Company (UK) Ltd., Attention: Syndicate Department, 546 Fifth Avenue, New York, NY 10036, by telephone at (212) 953-4900 or by email at syndicate@laidlawltd.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About MabVax Therapeutics Holdings, Inc.

MabVax Therapeutics Holdings, Inc. is a clinical stage oncology drug development company focused on the development of human antibody-based products and vaccines to address unmet medical needs in the treatment of cancer. MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against certain solid tumor cancers with the Company's proprietary vaccines. MabVax is preparing to file this year two investigational new drug applications, or INDs, for Phase 1 clinical trials of the Company's fully human antibody HuMab 5B1. One IND will be for a new generation HuMab 5B1-based PET imaging product for the diagnosis of pancreatic cancer. The second IND is for the HuMab 5B1 antibody as a treatment for metastatic pancreatic and colon cancer. First-in-human dosing for both products will occur at the end of 2015 or early 2016. MabVax has the exclusive license to a portfolio of therapeutic vaccines from Memorial Sloan Kettering Cancer Center. MabVax has two cancer vaccines targeting recurrent sarcoma and ovarian cancer in proof of concept Phase II multi-center clinical trials, and a vaccine targeting neuroblastoma that will be ready for Phase II clinical trial in 2016. Additional information about the Company is available at www.mabvax.com.

Forward-Looking Statements

Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements contained in this release relate to, among other things, the offering and, expected use of proceeds from the offering.   They are generally identified by words such as "believes," "may," "expects," "anticipates," "should'" and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company's beliefs and assumptions as of the date of this release. The Company's actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports filed with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

Contacts:

 



Jody Cain



Senior Vice President



LHA



310-691-7100



jcain@LHAI.com 






Robert B. Prag                                                  

Scott Wilfong


President                                              

President


The Del Mar Consulting Group, Inc.    

Alex Partners, LLC      


858-794-9500           

425-242-0891


bprag@delmarconsulting.com                

scott@alexpartnersllc.com 


 

SOURCE MabVax Therapeutics Holdings, Inc.



RELATED LINKS

http://www.mabvax.com